0001415889-24-018442.txt : 20240628 0001415889-24-018442.hdr.sgml : 20240628 20240628163048 ACCESSION NUMBER: 0001415889-24-018442 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240626 FILED AS OF DATE: 20240628 DATE AS OF CHANGE: 20240628 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McNulty Alana B. CENTRAL INDEX KEY: 0001606086 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40475 FILM NUMBER: 241086193 MAIL ADDRESS: STREET 1: C/O LUMENA PHARMACEUTICALS, INC. STREET 2: 12531 HIGH BLUFF DRIVE, SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Janux Therapeutics, Inc. CENTRAL INDEX KEY: 0001817713 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 822289112 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10955 VISTA SORRENTO PARKWAY STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 751-4493 MAIL ADDRESS: STREET 1: 10955 VISTA SORRENTO PARKWAY STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 form4-06282024_040643.xml X0508 4 2024-06-26 0001817713 Janux Therapeutics, Inc. JANX 0001606086 McNulty Alana B. C/O JANUX THERAPEUTICS, INC. 10955 VISTA SORRENTO PARKWAY, SUITE 200 SAN DIEGO CA 92130 true false false false 0 Common Stock 2024-06-26 4 A 0 2500 0 A 2500 D Stock Option (right to buy) 39.80 2024-06-26 4 A 0 8350 0 A 2034-06-25 Common Stock 8350 8350 D Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 26, 2025 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date. The shares subject to the option will vest in equal monthly installments over the 12 months following June 26, 2024, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date. /s/ Maria Dobek, Attorney-in-Fact 2024-06-27